Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Rating of "Buy" by Brokerages

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been given an average recommendation of "Buy" by the nine brokerages that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $25.5714.

A number of brokerages have weighed in on STOK. Wedbush lifted their target price on Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Jefferies Financial Group began coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 target price for the company. Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Needham & Company LLC reiterated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, HC Wainwright lowered their target price on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th.

Insider Activity at Stoke Therapeutics

In other news, insider Barry Ticho sold 4,504 shares of the business's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.82, for a total transaction of $57,741.28. Following the completion of the sale, the insider owned 16,775 shares in the company, valued at $215,055.50. The trade was a 21.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, General Counsel Jonathan Allan sold 13,712 shares of the business's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $15.00, for a total value of $205,680.00. Following the sale, the general counsel owned 19,631 shares of the company's stock, valued at approximately $294,465. This represents a 41.12% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,432 shares of company stock valued at $345,775. Corporate insiders own 9.50% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

Several institutional investors have recently bought and sold shares of STOK. GAMMA Investing LLC grew its holdings in Stoke Therapeutics by 1,842.0% during the first quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after buying an additional 5,084 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Stoke Therapeutics by 461.0% during the second quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after buying an additional 3,591 shares in the last quarter. AlphaQuest LLC bought a new stake in Stoke Therapeutics during the first quarter worth $72,000. Finally, US Bancorp DE grew its holdings in Stoke Therapeutics by 9,743.9% during the first quarter. US Bancorp DE now owns 11,222 shares of the company's stock worth $75,000 after buying an additional 11,108 shares in the last quarter.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $18.51 on Tuesday. The firm has a market cap of $1.01 billion, a P/E ratio of 21.78 and a beta of 1.15. The stock's 50 day moving average is $12.70 and its 200 day moving average is $10.20. Stoke Therapeutics has a one year low of $5.35 and a one year high of $18.60.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. The business had revenue of $13.82 million during the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. Equities analysts anticipate that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.